Literature DB >> 19026601

Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.

Wenjiang Zhang1, Lesley Seymour, Eric X Chen.   

Abstract

A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma. Plasma ultrafiltrates were precipitated with acetonitrile and separation was performed on a 250 mm Beckman ODS reverse phase column using a gradient mobile phase. The mass spectrometer was operated in positive ionization mode using TurboionSpray and precursor-product ion combinations of m/z 391.1-->305.1 and 371.1-->247.0 were monitored for oxaliplatin and carboplatin, the internal standard, respectively. The lower limit of quantitation for oxaliplatin was 20 ng/ml. The linear range of the method was 20-1000 ng/ml. The between- and within-day relative standard deviations ranged from 3.1 to 7.7%, and accuracy was within 5%. This method was successfully applied in a clinical study of oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026601     DOI: 10.1016/j.jchromb.2008.10.055

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Ultrasensitive and selective molecularly imprinted electrochemical oxaliplatin sensor based on a novel nitrogen-doped carbon nanotubes/Ag@cu MOF as a signal enhancer and reporter nanohybrid.

Authors:  Mater H Mahnashi; Ashraf M Mahmoud; Khalid Alhazzani; A Z Alanazi; Ali Mohammed Alaseem; Mohammad M Algahtani; Mohamed M El-Wekil
Journal:  Mikrochim Acta       Date:  2021-03-12       Impact factor: 5.833

2.  P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach.

Authors:  France Massicot; Guillaume Hache; Ludivine David; Dominique Chen; Charlotte Leuxe; Laure Garnier-Legrand; Patrice Rat; Olivier Laprévote; François Coudoré
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

3.  A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Authors:  S Sahebjam; P L Bedard; V Castonguay; Z Chen; M Reedijk; G Liu; B Cohen; W-J Zhang; B Clarke; T Zhang; S Kamel-Reid; H Chen; S P Ivy; A R A Razak; A M Oza; E X Chen; H W Hirte; A McGarrity; L Wang; L L Siu; S J Hotte
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

4.  A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Authors:  Suzanne Richter; Philippe L Bedard; Eric Xueyu Chen; Blaise A Clarke; Ben Tran; Sebastien J Hotte; Anastasios Stathis; Hal W Hirte; Albiruni R A Razak; Michael Reedijk; Zhuo Chen; Brenda Cohen; Wen-Jiang Zhang; Lisa Wang; S Percy Ivy; Malcolm J Moore; Amit M Oza; Lillian L Siu; Elaine McWhirter
Journal:  Invest New Drugs       Date:  2013-05-05       Impact factor: 3.850

5.  Population Pharmacokinetic Model-Based Evaluation of Intact Oxaliplatin in Rats with Acute Kidney Injury.

Authors:  Shinji Kobuchi; Miyu Kai; Yukako Ito
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

6.  Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats.

Authors:  Xiuqing Gao; Robert Y L Tsai; Jing Ma; Yang Wang; Xiaohua Liu; Dong Liang; Huan Xie
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.